EXCERPT:
Novartis is building a 46,000-square-foot RLT manufacturing facility in Denton, Texas — its fifth US site and part of a $23 billion domestic investment. Radioligand therapy manufacturing remains one of the most specialized and capacity-constrained areas in the industry.
CONTENT:
Novartis has announced plans to establish a new 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas. The facility will be the company’s fifth RLT site in the US and its first in Texas, part of a broader $23 billion US investment commitment.
Radioligand therapies — which combine a targeting molecule with a radioactive payload — represent one of the fastest-growing and most operationally demanding modalities in oncology. Manufacturing requires specialized radiation handling infrastructure, short product shelf lives due to isotope decay, and tightly controlled logistics from production to patient.
The capacity expansion signals Novartis’s confidence in RLT as a long-term commercial platform following the success of Lutathera and Pluvicto. For the broader industry, it also highlights an area where manufacturing infrastructure continues to lag behind clinical demand — a gap that creates both challenge and opportunity for specialized service providers.